LeeAnn Talarico

Title: LeeAnn Talarico: Innovator in Cancer Treatment

Introduction

LeeAnn Talarico is a prominent inventor based in Cambridge, MA, known for her significant contributions to the field of cancer treatment. With a total of two patents to her name, she has made strides in developing innovative therapies that target specific cancer cells.

Latest Patents

Her latest patents include "BCMA chimeric antigen receptors and uses thereof," which provides a BCMA targeting chimeric antigen receptor (CAR) that comprises a BCMA binding region and an intracellular costimulatory domain derived from DAP10. This invention also includes engineered immune effector cells, such as NK cells, that utilize these chimeric antigen receptors. Additionally, she holds a patent for "Compositions targeting BCMA and methods of use thereof," which relates to BCMA binders, including antibodies and CAR constructs that specifically bind to BCMA. These innovations enhance the efficacy of NK cells in killing cancer cells and include therapeutic uses of the BCMA binders and CARs.

Career Highlights

LeeAnn has worked with notable organizations, including Takeda Pharmaceutical Company Limited and the University of Texas System. Her work in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of her notable coworkers include Michael David Curley and Ertan Eryilmaz, who have also played significant roles in advancing cancer research.

Conclusion

LeeAnn Talarico's innovative work in developing BCMA-targeting therapies showcases her commitment to improving cancer treatment. Her patents reflect her expertise and dedication to advancing medical science.